By. Kellogg Parsons, MD
Date: 12/07/2023
Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics, joins him. As the interview unfolds, Dr. Parsons shares insights into the preclinical data of MBRC 101, a drug targeting the receptor tyrosine kinase.
In their discussion, Dr. Parsons discusses the applications of MBRC 101 in advanced metastatic solid tumors, particularly in breast cancer subtypes like triple-negative and H.R. positive HER2-negative. The uniqueness of EphA5, highly expressed in cancer cells with minimal presence in normal tissues, makes it a prospect for targeted cancer therapy.
Moving on to the pharmacokinetic aspects, Dr. Parsons sheds light on the significance of single and multiple dose PK profiles. He explains that these profiles, derived from Phase 1 studies, play a role in determining the safety and optimal dosage of MBRC 101 for future phases.
Wilbanks then delves into the study design, focusing on the non-randomized sequential assignment and the role of the Safety Review Committee. Dr. Parsons clarifies that this approach, common in Phase 1 studies, allows for meticulous monitoring of patient safety at each dose escalation, ensuring a careful progression through the trial phases.
The interview further explores the primary and secondary outcome measures, encompassing adverse events, response rates, and survival durations. Dr. Parsons elucidates how these measures collectively provide an assessment of MBRC 101’s safety, efficacy, and potential clinical benefits.
The conversation concludes with considerations for the study’s success, where Dr. Parsons highlights the importance of monitoring emerging data and tumor-specific responses. The interview wraps up with gratitude from both sides, emphasizing the collaborative effort in advancing medical knowledge at SABCS 2023.